Recently, research on new biomarkers for CRMO diagnosis and monitoring CRMO progression has been done by Hofmann et al. It showed that some changes in interleukin levels (IL-6, IL-12, eotaxin and others) were significantly altered during the CRMO disease course, meaning they could potentially be used as CRMO activity markers [37]. This evidence concerns the gene CCL11 and chronic recurrent multifocal osteomyelitis.